Gilead Sciences (GILD) PT Raised to $111 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Evercore ISI Says Gilead Sciences (GILD) Tenofovir Risk 'waning'
January 20, 2023 12:04 PM ESTEvercore ISI analyst Umer Raffat reiterated an Outperform rating and {REMOVEPT} price target on Gilead Sciences (NASDAQ: GILD).
The analyst comments "tenofovir litigation is waning"
For an analyst ratings summary and ratings history on Gilead Sciences... More
